Unique Challenges
Why Infectious Disease BRA Is Different
Infectious disease therapies operate under unique constraints — evolving pathogen landscapes, massive population-scale safety monitoring for vaccines, and compressed development timelines during pandemic response that demand specialized BRA approaches.
Resistance Signal Monitoring
Antimicrobial resistance (AMR) introduces dynamic benefit-risk profiles that shift over time as resistance patterns evolve. Antibiotics and antifungals require continuous monitoring of MIC creep, cross-resistance emergence, and microbiome disruption signals. BRA must account for both individual patient risk and population-level resistance selection pressure — a dual consideration unique to infectious disease therapeutics.
Vaccine Safety Surveillance
Vaccines administered to millions of healthy individuals require extraordinarily sensitive safety monitoring with very low signal-to-noise ratios. Rare adverse events occurring at 1-in-100,000 or 1-in-million rates — such as myocarditis, thrombosis with thrombocytopenia, or Guillain-Barre syndrome — must be detected rapidly against high background rates in large populations, demanding specialized statistical methods and real-time data integration.
Pandemic Timeline Compression
Emergency Use Authorization (EUA) and conditional approval pathways compress typical development timelines from years to months, requiring rapid benefit-risk assessment with limited safety databases. Post-authorization safety monitoring must compensate for truncated pre-approval evaluation, with real-time signal detection systems processing millions of adverse event reports within weeks of mass vaccination or treatment deployment.
Platform Capabilities
How ArcaScience Addresses Infectious Disease BRA Challenges
Our three integrated modules — Data Intelligence, Decision Intelligence, and Automated Outputs — are configured for Infectious Disease-specific benefit-risk assessment workflows.
Infectious Disease Data Coverage
Comprehensive infectious disease data from 14,200+ clinical trials, 22B+ adverse event records spanning FAERS, EudraVigilance, VigiBase, and VAERS. Integrated AMR surveillance data from GLASS, EARS-Net, and ATLAS databases. Real-time vaccine safety feeds from V-safe, the Vaccine Safety Datalink (VSD), and BEST Initiative sentinel systems covering 180+ countries.
Explore Data Engine →TA-Specific AI Models
8 AI models trained specifically on infectious disease safety and efficacy patterns, including rapid signal detection for vaccine-associated adverse events, AMR trend prediction from susceptibility data, and pandemic-speed sequential analysis. Bayesian self-controlled case series (SCCS) and tree-temporal scan statistics optimized for rare vaccine safety signal detection in large populations.
Explore AI Models →Infectious Disease Regulatory Outputs
Submission-ready vaccine safety reports, AMR monitoring dashboards, pandemic rapid BRA documents, PSUR/PBRER with infectious disease-specific safety sections, and REMS/RMP deliverables. Outputs formatted for FDA, EMA, WHO prequalification, and PMDA requirements, including EUA-specific benefit-risk frameworks and ACIP/JCVI presentation-ready safety summaries.
Explore Outputs →Safety Intelligence
Infectious Disease Adverse Event Landscape
Key safety signal categories tracked across anti-infective and vaccine programs, with AI-powered detection optimized for both individual therapeutics and population-scale immunization campaigns.
Vaccine-Associated Myocarditis
Myocarditis and pericarditis following mRNA vaccination, predominantly in young males — requiring age-sex stratified signal detection, background rate comparison, and outcome severity assessment for ongoing benefit-risk evaluation.
Thrombosis with Thrombocytopenia
Vaccine-induced immune thrombocytopenia and thrombosis (VITT) — a novel syndrome requiring new case definitions, specialized laboratory markers (anti-PF4 antibodies), and rapid regulatory action frameworks.
Hepatotoxicity
Drug-induced liver injury from anti-infective agents including anti-tuberculosis regimens (isoniazid, rifampicin), antifungals (voriconazole), and antiretrovirals — requiring Hy's Law analysis and DILI network pattern recognition.
Clostridioides difficile Infection
Antibiotic-associated C. difficile colitis driven by microbiome disruption — a critical secondary infection risk requiring microbiome impact profiling and comparative safety assessment across antibiotic classes.
QT Prolongation
Cardiac conduction abnormalities with fluoroquinolones, macrolides, and azole antifungals — requiring thorough QT studies, drug interaction modeling, and real-world cardiac safety monitoring in polypharmacy populations.
Nephrotoxicity
Renal toxicity from aminoglycosides, vancomycin, amphotericin B, and antiviral agents (tenofovir) — requiring therapeutic drug monitoring integration, creatinine clearance trending, and dose-adjustment safety algorithms.
Case Study — Infectious Disease
mRNA Vaccine — Post-Authorization Safety Monitoring
Challenge
A major vaccine manufacturer needed to establish real-time post-authorization safety surveillance for an mRNA vaccine platform deployed across 90+ countries. The program required near-real-time myocarditis signal quantification, age-sex stratified observed-vs-expected analysis, and automated regulatory reporting to FDA, EMA, and 30+ national regulatory authorities simultaneously — all within weeks of initial deployment rather than the typical months-long pharmacovigilance cycle.
Approach
ArcaScience deployed pandemic-optimized AI models processing VAERS, V-safe, EudraVigilance, and VigiBase feeds in near-real-time. Sequential probability ratio testing (SPRT) and self-controlled case series analysis enabled continuous signal evaluation against dynamically updated background rates. Automated PADER (Post-Authorization Data Entry and Review) reports were generated weekly for FDA and monthly PSUR supplements for EMA.
Signal detection turnaround
Countries monitored simultaneously
Reduction in reporting cycle time
Dr. Elena Vasquez
Global Head of Vaccine Safety, Major Vaccine Manufacturer
Regulatory Intelligence
Infectious Disease Regulatory Context
Key regulatory considerations and guidance specific to infectious disease and vaccine benefit-risk assessment for FDA, EMA, WHO, and PMDA submissions.
Resources
Related Infectious Disease Resources
Real-Time Vaccine Safety Surveillance: AI Methods & Validation
Comprehensive methodology for AI-driven vaccine adverse event detection at scale, including sequential analysis approaches, background rate estimation, and multi-database signal confirmation strategies.
Download Whitepaper →AMR and Benefit-Risk: Integrating Resistance Data into BRA Frameworks
How antimicrobial resistance patterns should influence benefit-risk assessment for new antibiotics, including population-level resistance selection modeling and stewardship-aligned BRA approaches.
Read Article →Pandemic Preparedness: Building Rapid BRA Capabilities
On-demand webinar covering lessons learned from COVID-19 vaccine safety surveillance, with frameworks for building pandemic-ready benefit-risk assessment infrastructure.
Watch Recording →